BMN 333 + Vosoritide Injection [Voxzogo]
Phase 2/3Recruiting 0 watching 0 views this week📈 Rising
62
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Achondroplasia
Conditions
Achondroplasia
Trial Timeline
Feb 1, 2026 → Sep 1, 2029
NCT ID
NCT07441876About BMN 333 + Vosoritide Injection [Voxzogo]
BMN 333 + Vosoritide Injection [Voxzogo] is a phase 2/3 stage product being developed by BioMarin Pharmaceutical for Achondroplasia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07441876. Target conditions include Achondroplasia.
Hype Score Breakdown
Clinical
22
Activity
15
Company
7
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07441876 | Phase 2/3 | Recruiting |
Competing Products
20 competing products in Achondroplasia